Anatara Lifesciences Advances GaRP-IBS Trial Recruitment

Anatara Lifesciences Ltd (AU:ANR) has released an update.

Anatara Lifesciences is making progress in the recruitment for Stage 2 of its GaRP-IBS clinical trial, with around 40 participants enrolled and more than 20 in final screening. The company has expanded the trial sites to Adelaide and Queensland’s Sunshine Coast, which have significantly contributed to recruitment efforts. Anatara aims to complete recruitment by Q4 2024 and expects to release headline results in Q1 2025.

For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.